Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
Holding IRON?
Track your performance easily
IRON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.60 - $77.60
Previous Close$65
Volume666.44K
Average Volume (3M)268.30K
Market Cap
$1.88B
Enterprise Value$1.38B
Total Cash (Recent Filing)$500.94M
Total Debt (Recent Filing)$1.84M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Mar 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.66
Shares Outstanding29,725,763
10 Day Avg. Volume570,222
30 Day Avg. Volume268,298
Standard Deviation0.21
R-Squared0.02
Alpha-0.00838
Financial Highlights & Ratios
Price to Book (P/B)3.95
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-30.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.60
Forecast
1Y Price Target
$88.56Price Target Upside36.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Disc Medicine News
Bulls Say, Bears Say
Bulls Say
Financial OutlookBitopertin could be a significant drug with orphan indication and limited competition, potentially reaching a value of $600 million by 2030 with blockbuster potential.
Market PotentialBitopertin is likely to reach the market faster and with a higher probability, potentially becoming the first disease-modifying agent with a clear and direct mechanism of action for its condition.
Regulatory ApprovalPositive feedback from an End-of-Phase 2 meeting with FDA could allow for a substantially accelerated path to market for lead asset bitopertin in erythropoietic protoporphyria.
Bears Say
Clinical TrialsThe Phase 2 AURORA study did not show significant improvements in light tolerance due to a greater-than-expected placebo response.
Financial PerformanceR&D expenses jumped 94.1% YoY to $23.5M from $12.1M in the same period last year.
Investor SentimentShort interest is relatively high at 9.5% of the float, indicating some investor skepticism.
---
Ownership Overview
34.22% Insiders
12.17% Mutual Funds
0.02% Other Institutional Investors
44.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $25.60 and its highest was $77.60 in the past 12 months.
What is Disc Medicine’s market cap?
Currently, no data Available
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Mar 28, 2025 which is in 138 days.
How were Disc Medicine’s earnings last quarter?
Currently, no data Available
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 29,725,763 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Disc Medicine?
Among the largest hedge funds holding Disc Medicine’s share is Deerfield Management Company, LP. It holds Disc Medicine’s shares valued at 46M.
---
Disc Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.56 (36.25% Upside)
$88.56 (36.25% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 241.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 39.5%
Last 30 Days ▲ 34.5%
Last 30 Days ▲ 34.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.12%
12-Months-Change
Fundamentals
Return on Equity
-21.16%
Trailing 12-Months
Asset Growth
32.81%
Trailing 12-Months
Company Description
Disc Medicine
FS Development Corp is a blank check company.
---
IRON Stock 12 Month Forecast
Average Price Target
$88.56
▲(36.25% Upside)
Technical Analysis
Best Analysts Covering IRON
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+33.18%
reiterated a buy rating 6 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +33.18% per trade.
---